Pegcetacoplan Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels at or Above 10 Grams per Deciliter: A Post Hoc Analysis (AAMDS 2022) - Apellis Medical Hub

Pegcetacoplan Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels at or Above 10 Grams per Deciliter: A Post Hoc Analysis

Share Via Email

Back to Conference Resources

PNH Congress Presentations The Aplastic Anemia and MDS International Foundation (AAMDS) 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.